News
-
-
-
-
PRESS RELEASE
PolyPeptide Group: Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
Samsung Biologics announces tender offer to acquire PolyPeptide Group AG at CHF 44.31 per share, reflecting growth and profitability. PolyPeptide reports marked acceleration in H1 2026 results -
PRESS RELEASE
WALLIX outperforms in cautious markets / 2026 targets confirmed.
WALLIX reports +19.4% MRR growth and 14.2% H1 turnover rise to €20.6 million. Confirmed 2026 financial targets: hypergrowth in recurring business, positive earnings, free cash flow. Strong growth drivers: Key Account acquisition, AI, regulation, digital sovereignty -
-
-
-
-